Instructor in Medicine, Massachusetts General Hospital
Oncology
Dr. Lawrence S. Blaszkowsky, MD
|
|
Give Review
Lawrence Blaszkowsky is an expert in the field of Oncology. He studied medicine at Mount Sinai School of Medicine. He has 1 awards "Meaningful Use Stage 1 Certification". Lawrence Blaszkowsky is also published. He has 67 publications published. The lastest publication: "Treatment of advanced and metastatic pancreatic cancer.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.
- Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic Cancer.
- Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
- Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal Cancer.
- A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma.
- Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder Cancer.
- A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreat...
- Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
- Caring for One of Our Own.
- Mutational analysis and clinical correlation of metastatic colorectal Cancer.
- Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
- Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic Cancer.
- Phase 1 study of N (1),N (11)-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma.
- Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer.
- Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic Cancer treated with intraoperative radiotherapy at the Mas...
- Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic Cancer.
- A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic Neuroendocrine tumor.
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
- Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study.
- Factors Affecting Survival following Chemoembolization with Doxorubicin-eluting Microspheres for Inoperable Hepatocellular Carcinoma.
- Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a "True" R0 Resection?
- Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors.
- Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer.
- Dose-Volume Effects on Patient-Reported Acute Gastrointestinal Symptoms During Chemoradiation Therapy for Rectal Cancer.
- Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic Cancer.
- A phase 2 study of oral MKC-1, an inhibitor of importin-?, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic Cancer.
- IntraDuctal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy.
- A multicenter phase II trial of single-agent cetuximab in advanced Esophageal and gastric adenocarcinoma.
- Case records of the Massachusetts General Hospital. Case 13-2011. A 49-year-old man with adenocarcinoma of the rectum.
- Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
- Tolerability of Combined Modality Therapy for Rectal Cancer in Elderly Patients Aged 75 Years and Older.
- Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor.
- Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic Ductal adenocarcinoma of the head.
- Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.
- Dose-painted Intensity-modulated Radiation Therapy for Anal Cancer: A Multi-institutional Report of Acute Toxicity and Response to Therapy.
- A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid Tumors.
- The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal Cancer surgery.
- Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
- Outcomes and tolerability of chemoradiation therapy for pancreatic Cancer patients aged 75 years or older.
- Toxicity and outcomes after chemoradiation for esophageal Cancer in patients age 75 or older.
- Added value of selected images embedded into radiology reports to referring clinicians.
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract Cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinica...
- Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
- Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric Cancer.
- Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic Cancer.
- MDM2 promoter polymorphism and pancreatic Cancer risk and prognosis.
- Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder Cancer.
- Case report: an unusual case of Adrenal neuroblastoma in pregnancy.
- Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic Cancer.
- Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
- Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal Cancer.
- Laparoscopic scar: a mimicker of Sister Mary Joseph''s nodule on positron emission tomography/CT.
- Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal Cancer.
- Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
- Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in r...
- Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the Liver.
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal Cancer.
- Circulating tumor cells and serum tumor biomarkers in small cell lung Cancer.
- High dose radiation therapy and chemotherapy as inDuction treatment for stage III nonsmall cell lung carcinoma.
- A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic Cancer: an Eastern Cooperative Oncology Group Study (E3296).
- Treatment of advanced and metastatic pancreatic Cancer.
- The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thr...
- All-trans retinoic acid for the treatment of newly diagnosed Acute promyelocytic leukemia.
- A prospective feasibility study of respiratory-gated proton beam therapy for Liver tumors.
- Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic Cancer may not impact local control.
- Irradiation of FDG-PET-Defined Active Bone Marrow Subregions and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation.
Schools
Upstate Medical University College of Health Professions
Mt Sinai Hospital
New Eng Mc Tufts University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
Tufts Medical Center -
Mount Sinai School of Medicine -
State University of New York Upstate Medical University
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1225028137 | |
| NPPES Provider LastName | BLASZKOWSKY | |
| NPPES Provider FirstName | LAWRENCE | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 351.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 29.0 | |
| Percent Opioid Claims | 8.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225028137 |
| Last Name Of The Provider | BLASZKOWSKY |
| First Name Of The Provider | LAWRENCE |
| View All |
Similar Doctors
|
|
Dr. Lori J. Wirth, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Joan Sully, NP |
|
|
Dr. Andrew M. Brunner, MD |
|
|
Dr. Megan L. Insco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Ligibel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William A. Wood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam F. Binder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shuchi S. Pandya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ayad Hamdan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hao Zhu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacy W. Gray, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy S. Garrett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward J. Benz Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Rabin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frank S. Hodi Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nageatte Ibrahim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Friedlander Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter C. Enzinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John K. Erban III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lauren J. Oshry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xuejun Tian, MD |